Company news
aTyr Pharma, Inc. news in 2022
aTyr Pharma, Inc.'s news releases, calls and decks from 2022, newest first.
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
December 14, 2022
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
November 9, 2022
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 8, 2022
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 10, 2022
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
September 28, 2022
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
September 26, 2022
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
September 12, 2022
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
August 14, 2022
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
August 10, 2022
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
June 13, 2022
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
May 16, 2022
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
May 15, 2022
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
May 8, 2022
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
April 12, 2022
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
April 10, 2022
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
March 31, 2022
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
March 13, 2022
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
March 9, 2022
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
January 12, 2022
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
January 5, 2022
Decks in 2022
- Technical Presentation (May 2022)
Technical · 32 slides · May 17, 2022